Sistemic hires more staff
Moves to larger premises that will become new global hq
The company says this will enable it to fulfil current contracts more rapidly, while providing further capacity for newly acquired and future contracts. It will also support the expansion of its key internal r&d programmes in drug toxicology and stem cell characterisation.
The expansion programme will also see the company grow its US commercial operations by developing its Boston location and opening an office in California.
David Mallinson, who previously worked for Merck Sharpe Dohme (MSD), has joined Sistemic as a senior scientist and will lead new projects at the expanded facility.
Max Bylesjo, previously at Almac Group, has joined as senior bioinformatician and will focus on developing Sistemic’s data processing technology.
The new Sistemic headquarters will dedicate 60% of its space to laboratory facilities, equipped with state-of-the-art technology, and 40% as new commercial areas.
You may also like
Research & Development
Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases
The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases